Difference Between Opioids and Opiates

| September 18, 2019

article image
The difference between opioids and opiates is subtle enough that most people use the words interchangeably. After all, they both come from the poppy plant. The biggest difference is that opiates are natural drugs and opioids are synthetic drugs. They both have the same effect on the mind and can cause the same side effects.

Spotlight

Pierre Fabre Group

Pierre Fabre is the 2nd largest dermo-cosmetics laboratory in the world and the 2nd largest private French pharmaceutical group. In 2017, it generated 2,318 million euros in net sales, of which 62% came from its international business and 62% from its dermo-cosmetics division. Pierre Fabre, which has always been headquartered in the South-West of France, owns subsidiaries in 43 countries, enjoys distribution agreements in over 130 countries and counts around 13,500 employees worldwide. Pierre Fabre’s portfolio represents a continuum of activities spanning from prescription drugs and consumer health care products to dermo-cosmetics. In 2017, Pierre Fabre dedicated almost 143 million euros to R&D, shared between oncology, dermatology, the central nervous system, consumer health care and dermo-cosmetics.

OTHER ARTICLES

Pharmacist eCare Plan - the newest disrupter in health data exchange?

Article | February 25, 2020

Every member of the health care team shares a common goal of optimizing patient outcomes. Yet each specialty and position of the healthcare team has a unique workflow facilitated by various tools, from an operative report to a progress note. In this regard the pharmacist plays a pivotal function in medication management and requires documentation specific to that role. The Pharmacist eCare Plan (PeCP) allows for an interoperable note to be used in the pharmacy to assist in the exchange of patient information, including active medication list, laboratory results, and payer information. To allow for this, a new type of clinical document architecture for the PeCP was created and standardized for use across pharmacies.

Read More

The Future of Pharma Beyond Blockbusters

Article | March 17, 2020

We’ve all heard the saying “treat the patient, not the disease”, and this couldn’t be truer in today’s ever-changing pharmaceutical landscape. We are living in a time of revolution – advancements in genomics and technology are improving our ability to develop precise drugs and targeted therapies, rather than focusing on a one size fits all approach. Each individual’s genetic makeup is slightly different from everyone else’s,

Read More

Coronavirus Pandemic Brings Hundreds Of U.S. Clinical Trials To A Halt

Article | April 11, 2020

Rene Roach fired off a quick email in late March for an update on a colorectal cancer clinical trial for which she hoped to qualify. Worried about the coronavirus, she asked, almost as an afterthought, whether the study had been put on hold because of the pandemic.The answer crushed her: It had been. "That's when COVID-19 shut down everything," says Roach, 50, of Germantown, Md. Roach assumed that there would be workarounds for patients like her, who have stage IV cancer. These patients often depend on clinical trials as their best chance to knock cancer out when other therapies have failed. For now, she's being treated with traditional chemotherapy, but she was counting on the drug cocktail from the clinical trial. She figures if chemo was going to rid her body of cancer for good, it would have done so already.

Read More

Roche Prepares to Launch COVID-19 Antibody Test System

Article | April 17, 2020

Swiss pharma giant Roche is joining the race to develop a test for COVID-19 antibodies in people who have been exposed to the disease. This morning, Roche announced the development and upcoming launch of its Elecsys Anti-SARS-CoV-2 serology test to detect antibodies in people who have been exposed to the SARS-CoV-2, the virus that causes COVID-19. Roche is eying May for the launch of the test in Europe and is in talks with the U.S Food and Drug Administration for emergency approval of the system. Antibody testing is central to help identify people who have been infected by the virus, especially those who may have been infected but did not display symptoms, the company said. Roche noted that as more information becomes available about immunity levels to COVID-19, society can return to a sense of normal much more quickly. Roche’s test will join a number of other antibody tests that have recently come on the market. Earlier this month the U.S. Food and Drug Administration approved the first blood test for COVID-19 antibodies.

Read More

Spotlight

Pierre Fabre Group

Pierre Fabre is the 2nd largest dermo-cosmetics laboratory in the world and the 2nd largest private French pharmaceutical group. In 2017, it generated 2,318 million euros in net sales, of which 62% came from its international business and 62% from its dermo-cosmetics division. Pierre Fabre, which has always been headquartered in the South-West of France, owns subsidiaries in 43 countries, enjoys distribution agreements in over 130 countries and counts around 13,500 employees worldwide. Pierre Fabre’s portfolio represents a continuum of activities spanning from prescription drugs and consumer health care products to dermo-cosmetics. In 2017, Pierre Fabre dedicated almost 143 million euros to R&D, shared between oncology, dermatology, the central nervous system, consumer health care and dermo-cosmetics.

Events